Hepatocellular carcinoma recurrence rate in HCV infected patients treated with direct antiviral agents. A single center experience

Granata, R.; Costanzo, Giovan Giuseppe Di; Zamparelli, Marco Sanduzzi; Guarino, M.; Cordone, G; Tortora, Raffaella

doi:10.1016/s0168-8278(17)31918-9

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, 20 studies were excluded because they presented data on HCC occurrence but not recurrence, 11 had insufficient data for abstraction, 5 had overlapping cohorts, 4 exclusively characterised post‐transplant HCC recurrence, and 7 studies were excluded for lack of original data (Figure S1). Finally, review of American Association for the Study of Liver Diseases, European Association for the Study of the Liver, and International Liver Cancer Association conference abstracts identified 7 additional studies and recursive literature searches identified 1 full‐length manuscript and 2 letters to the editor that met inclusion criteria, producing a total of 26 studies . The study by the ANRS collaborative study group included 2 distinct cohorts, yielding a total of 27 cohorts.…”

Section: Resultsmentioning

confidence: 99%

“…Nine studies compared HCC recurrence in DAA‐treated (n = 947) patients to interferon‐treated (n = 210) and/or untreated (n = 641) patients (Table ) . Five studies reported no significant difference in HCC recurrence between DAA‐treated and untreated patients in multivariable analyses, while 2 studies found significantly lower HCC recurrence among DAA‐treated patients.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review with meta‐analysis: recurrence of hepatocellular carcinoma following direct‐acting antiviral therapy

Saraiya

Yopp

Rich

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Systematic review with meta‐analysis: recurrence of hepatocellular carcinoma following direct‐acting antiviral therapy

Saraiya

Yopp

Rich

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Study characteristics were summarised in Tables and . Fifty‐six studies were included, with a total of 5522 patients with HCC, while 27 studies enrolled non‐HCC patients as control groups. Fifty‐three (95%) studies were observational cohorts (45 retrospective and eight prospective) and three studies were clinical trials.…”

Section: Resultsmentioning

confidence: 99%

Systematic review with meta‐analysis: effectiveness of direct‐acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma

Lockart

Alavi

et al. 2019

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Direct‐acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection is highly curative and tolerable. Among patients with hepatocellular carcinoma (HCC), optimal timing of DAA therapy remains unclear. Data on efficacy of DAA therapy in patients with HCC would inform this decision‐making. Aim To evaluate response to DAA therapy among patients diagnosed with HCV infection and HCC. Methods Bibliographic databases and conference abstracts were searched. Meta‐analysis was conducted to pool sustained virologic response (SVR) estimates. Results Fifty‐six studies with 5522 patients with HCV and HCC were included. Overall SVR was 88.3% (95% CI 86.1‐90.4). Twenty‐seven studies included patients with prior or present HCC (n = 3126) and patients without HCC (n = 49 138), in which SVR was 88.2% (95% CI 85.0‐91.4) and 92.4% (95% CI 91.1‐93.7) among patients with and without HCC, respectively (odds ratio: 0.54, 95% CI 0.43‐0.68, P < .001). In the subgroup analyses, higher SVR was seen in patients who received curative HCC management (SVR 90.4%, 95% CI 88.3‐92.4), or treated with sofosbuvir + NS5A inhibitor DAAs (SVR 96.9%, 95% CI 94.3‐99.4), or in patients with HCV genotype 1 infection (SVR 92.0%, 95% CI 88.1‐95.6). Conclusion Response to DAA therapy was lower in patients with HCC compared to those without HCC, regardless of cirrhosis status. Among HCC patients, there was an impact of proportion with curative HCC management on DAA therapy response.

show abstract

“…51 Granata et al reported that, after DAA treatment, the recurrence rate was 27.8% with a 7-month (range:3-15 months) follow-up period, indicating that the eradication of HCV did not reduce the risk of HCC recurrence in a prospectively single-center study. 52 A nationwide multicenter study conducted by the Japanese Red Cross Hospital Liver Study Group found no difference in early recurrence between DAA-treated and IFN-treated patients, and accurate data were not shown. 53 Waziry et al found no difference in the recurrence rate of HCC after DAA treatment and interferon treatment in a systematic review, meta-analyses, and meta-regression that recruited 17 qualified studies.…”

Section: Daa Therapy Cannot Increase the Risk Of Recurrence In Patienmentioning

confidence: 99%

<p>Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC</p>

Gao¹,

Zhan²,

Wang³

et al. 2020

JHC

View full text Add to dashboard Cite

Hepatitis C virus infection is a major cause of chronic hepatitis, leading to cirrhosis and hepatocellular carcinoma (HCC). Many studies agree that interferon (IFN)based antiviral therapy can reduce the risk of HCC recurrence in patients with chronic hepatitis C who have achieved a sustained virological response (SVR). The recent introduction of direct-acting antivirals (DAA) has resulted in excitingly high SVR rates. However, as an IFN-free regimen, DAAs only exert antiviral activity without an immune response. The benefit of DAA-based regimens for HCC recurrence in patients with cirrhosis and following successful curative treatment remains controversial. Additionally, the time span between curative-intent therapy and the DAA regimen is an independent risk factor for HCC recurrence, irrespective of the DAA response. HCC patients who are eligible for potentially curative therapy by liver resection or ablation should defer DAA therapy; however, the accurate timing remains unclear. In this study, we reviewed the timing of DAA initiation after curative treatment and its effect on the recurrence of related HCC.

show abstract

Hepatocellular carcinoma recurrence rate in HCV infected patients treated with direct antiviral agents. A single center experience

Cited by 5 publications

References 0 publications

Systematic review with meta‐analysis: recurrence of hepatocellular carcinoma following direct‐acting antiviral therapy

Systematic review with meta‐analysis: recurrence of hepatocellular carcinoma following direct‐acting antiviral therapy

Systematic review with meta‐analysis: effectiveness of direct‐acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma

<p>Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC</p>

Contact Info

Product

Resources

About